miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma

Background: Sorafenib constitutes a suitable treatment alternative for patients with advanced hepatocellular carcinoma (HCC) in whom atezolizumab + bevacizumab therapy is contraindicated. The aim of the study was the identification of a miRNA signature in liquid biopsy related to sorafenib response....

Descripción completa

Detalles Bibliográficos
Autores principales: de la Cruz-Ojeda, Patricia, Schmid, Tobias, Boix, Loreto, Moreno, Manuela, Sapena, Víctor, Praena-Fernández, Juan M., Castell, Francisco J., Falcón-Pérez, Juan Manuel, Reig, María, Brüne, Bernhard, Gómez-Bravo, Miguel A., Giráldez, Álvaro, Bruix, Jordi, Ferrer, María T., Muntané, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454520/
https://www.ncbi.nlm.nih.gov/pubmed/36078082
http://dx.doi.org/10.3390/cells11172673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454520/
https://www.ncbi.nlm.nih.gov/pubmed/36078082
http://dx.doi.org/10.3390/cells11172673

Ejemplares similares